Observational studyPloS one2025
Risk factors for human infection with mpox among the Mexican population with social security.
Observational study in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mpox: Characterization and clinical outcomes of patients in Colombian healthcare institutions.Global epidemiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 2022 mpox outbreak marked a significant shift in the epidemiology of this zoonotic disease, traditionally confined to Central and West Africa. With over 80 countries reporting cases, this outbreak was characterized by a rapid spread in non-endemic regions, leading to more than 70,000 confirmed cases globally.
objectiveTo quantify the cumulative incidence of mpox and identify associated factors of mpox among the Mexican population affiliated by the Mexican Social Security Institute during the 2022-2023 outbreak. MATERIAL AND
methodsA retrospective observational study using a cross-sectional survey to assess the cumulative incidence and factors associated with mpox. The cumulative incidence of laboratory confirmed mpox cases was calculated by dividing the number of confirmed cases by the insured population in the Mexican Social Security Institute as of mid-2022, per 100,000 individuals, this was analyzed by sex, age group, sexual orientation and people living with HIV. Logistic regression analyses were conducted to identify sociodemographic and clinical factors associated with mpox infection.
resultsA total of 2,956 probable cases were reported, with 1,744 (59%) laboratory-confirmed mpox cases. Most confirmed cases were male, with a median age of 32 years. The overall cumulative incidence was 4.05 per 100,000 persons, significantly higher in men and men who have sex with men. Logistic regression revealed that male sex was significantly associated with higher odds of laboratory-confirmed mpox. Age groups 30-34, 35-39, and 40-44 had an elevated risk of infection. Men who have sex with men showed a substantially increased likelihood of mpox, while individuals living with HIV were at higher risk compared to those without HIV. Key clinical predictors included fever, arm rash, and inguinal lymphadenopathy.
conclusionThe 2022 mpox outbreak revealed significant disparities in infection risk, particularly among men, men who have sex with men, and individuals living with HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.